VERU
Veru Inc. NASDAQ Listed Feb 11, 1999$2.97
Pre-mkt
$2.96
-0.34%
Mkt Cap $43.5M
52w Low $2.09
18.1% of range
52w High $6.95
50d MA $2.53
200d MA $2.73
P/E (TTM)
—
EV/EBITDA
—
P/B
2.4x
Debt/Equity
0.2x
ROE
-51.5%
P/FCF
-1.4x
RSI (14)
58.00
ATR (14)
$0.67
Beta
-1.34
50d MA
$2.53
200d MA
$2.73
Avg Volume
3.8M
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
48 NW 25th Street · Miami, FL 33127 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | BMO | -0.28 | -0.11 | +61.4% | 2.27 | +0.9% | -0.4% | -7.5% | +1.0% | +0.5% | -0.5% | — |
| Feb 11, 2026 | BMO | -0.47 | -0.26 | +44.7% | 2.30 | +0.4% | -2.6% | +2.2% | +2.6% | +3.0% | +2.9% | — |
| Dec 17, 2025 | BMO | -0.36 | -0.60 | -64.4% | 2.23 | +7.2% | +1.3% | +2.7% | -1.3% | +1.3% | +0.9% | — |
| Aug 12, 2025 | BMO | -0.55 | -0.50 | +9.1% | 3.17 | -0.9% | +7.6% | +8.8% | -3.2% | -2.2% | -7.7% | — |
| May 8, 2025 | BMO | -0.06 | -0.05 | +16.7% | 5.22 | -0.4% | -3.6% | +3.6% | -1.0% | -2.5% | +2.2% | — |
| Feb 13, 2025 | BMO | -0.08 | -0.07 | +12.5% | 5.26 | -1.1% | +2.9% | +1.8% | +8.9% | -1.7% | -2.9% | — |
| Dec 16, 2024 | BMO | -0.07 | -0.06 | +14.3% | 7.85 | -3.2% | -9.2% | -6.0% | -6.1% | +3.2% | -0.3% | — |
| Aug 8, 2024 | BMO | -0.06 | -0.07 | -16.7% | 8.10 | +1.2% | +1.7% | +1.1% | -1.1% | -2.9% | +5.0% | — |
| May 8, 2024 | BMO | -0.05 | -0.07 | -40.0% | 14.30 | +1.4% | -4.2% | -2.9% | +0.0% | +10.5% | +0.0% | — |
| Apr 1, 2024 | BMO | -2.35 | -0.82 | +65.1% | 7.60 | -0.1% | +1.8% | +7.1% | +0.1% | +11.4% | +11.4% | — |
| Dec 8, 2023 | BMO | -0.20 | -0.16 | +20.0% | 11.70 | -16.2% | -26.2% | -1.9% | -2.4% | -8.9% | +0.9% | — |
| Aug 10, 2023 | BMO | -0.20 | -0.13 | +35.0% | 10.90 | +1.8% | +4.6% | +0.0% | -1.8% | -3.6% | -4.6% | — |
| May 11, 2023 | AMC | -0.33 | -0.44 | -33.3% | 12.30 | +2.4% | -7.3% | -2.6% | -2.7% | +5.6% | -0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13 | Raymond James | Maintains | Outperform → Outperform | — | $3.17 | $3.14 | -0.9% | +7.6% | +8.8% | -3.2% | -2.2% | -7.7% |
| Jan 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.51 | $6.60 | +1.4% | +0.2% | +13.2% | +2.0% | -1.2% | -2.4% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.29 | $6.30 | +0.2% | +3.2% | -0.3% | -2.9% | +9.1% | -1.3% |
| Nov 5 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.34 | $8.30 | +13.1% | +1.0% | +0.3% | -1.2% | -0.3% | -1.4% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.30 | $13.20 | -0.8% | +0.0% | +10.5% | +0.0% | -6.8% | -3.6% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.30 | $16.30 | +0.0% | +0.6% | -0.6% | -12.3% | -4.2% | -2.9% |
| Apr 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $15.20 | $15.10 | -0.7% | +0.7% | -18.3% | -7.2% | +22.4% | -7.7% |
| Feb 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.40 | $4.28 | -2.7% | -6.6% | -7.5% | +2.1% | -2.6% | +10.3% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.00 | $8.05 | +0.6% | -2.5% | -3.6% | -4.4% | +1.4% | +1.6% |
| Jun 7 | Jefferies | Upgrade | Underperform → Hold | — | $11.30 | $11.40 | +0.9% | +8.0% | +7.4% | +0.0% | -3.1% | +3.9% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.40 | $11.40 | +0.0% | -2.6% | -2.7% | +5.6% | -0.9% | +0.9% |
| Apr 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.20 | $10.90 | -2.7% | -5.4% | -5.7% | +1.0% | -1.0% | +5.0% |
| Mar 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $20.70 | $20.00 | -3.4% | -11.1% | +1.1% | -14.0% | +8.1% | -8.1% |
| Feb 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $40.20 | $40.00 | -0.5% | -0.2% | +9.7% | +3.2% | +1.1% | -3.3% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.70 | $40.60 | +2.3% | +4.5% | -3.1% | -0.2% | +9.7% | +3.2% |
| Dec 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.60 | $56.00 | -1.1% | -1.6% | +4.7% | -6.2% | -1.8% | -1.1% |
| Dec 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $55.00 | $54.00 | -1.8% | +5.8% | -2.7% | -1.6% | +4.7% | -6.2% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $150.10 | $61.80 | -58.8% | -53.6% | -5.5% | -6.1% | +1.3% | -2.9% |
| May 18 | Brookline Capital | Maintains | Buy → Buy | — | $156.00 | $159.40 | +2.2% | -3.8% | -4.8% | -6.4% | +5.5% | -13.5% |
| May 13 | Jefferies | Maintains | Buy → Buy | — | $90.30 | $112.70 | +24.8% | +44.0% | +3.8% | +15.6% | -3.8% | -4.8% |
| Apr 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $122.80 | $136.10 | +10.8% | -18.5% | +42.9% | +4.5% | -20.4% | +6.2% |
| Apr 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $122.80 | $136.10 | +10.8% | -18.5% | +42.9% | +4.5% | -20.4% | +6.2% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $152.20 | $152.40 | +0.1% | -0.5% | -5.7% | -3.2% | +4.3% | -2.8% |
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $192.30 | $184.80 | -3.9% | -2.1% | +10.4% | -4.6% | -13.2% | -8.1% |
| Feb 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $139.20 | $152.00 | +9.2% | +38.4% | -0.2% | -2.1% | +10.4% | -4.6% |
| Dec 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $93.30 | $96.60 | +3.5% | +7.1% | -6.9% | -5.3% | +0.6% | +4.9% |
| Dec 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $97.00 | $114.00 | +17.5% | -3.8% | +7.1% | -6.9% | -5.3% | +0.6% |
| Dec 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $63.60 | $98.70 | +55.2% | +52.5% | -3.8% | +7.1% | -6.9% | -5.3% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.90 | $48.30 | +24.2% | +53.5% | +6.5% | +52.5% | -3.8% | +7.1% |
| May 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $39.70 | $40.00 | +0.8% | +1.3% | -1.2% | -1.8% | -2.6% | -2.1% |
No insider trades available.
8-K · 8.01
!! High
Veru Inc. -- 8-K 8.01: Material Event / Announcement
Jun 4
8-K
Veru Inc. -- 8-K Filing
May 13
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Verastem's executive transition effective March 12, 2026 creates uncertainty about strategic direction and leadership continuity, which could pressure the stock until market confidence in new leadership stabilizes.
Mar 13
8-K
Veru Inc. -- 8-K Filing
Veru Inc. is advancing its PLATEAU Phase 2b trial combining enobosarm with semaglutide for obesity treatment while reporting fiscal 2026 Q1 results, positioning the company's pipeline development.
Feb 11
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Alyeska Investment Group, L.p. | 1,000,000 | $2M | — | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 539,382 | $1M | New | Mar 2026 |
| 3 | Oppenheimer & Co Inc | 196,300 | $434K | Reduced | Mar 2026 |
| 4 | Millennium Management | 150,401 | $332K | Reduced | Mar 2026 |
| 5 | Choreo, Llc | 75,263 | $166K | — | Mar 2026 |
| 6 | Jane Street Group, Llc | 71,667 | $153K | New | Dec 2025 |
| 7 | Renaissance Technologies Llc | 69,250 | $153K | New | Mar 2026 |
| 8 | Raymond James Financial Inc | 67,561 | $149K | Reduced | Mar 2026 |
| 9 | Blair William & Co/il | 48,000 | $106K | — | Mar 2026 |
| 10 | Citadel Advisors Llc | 44,482 | $98K | Reduced | Mar 2026 |
| 11 | Adar1 Capital Management, Llc | 35,000 | $77K | New | Mar 2026 |
| 12 | Northern Trust Corp | 33,588 | $74K | — | Mar 2026 |
| 13 | Ubs Group Ag | 27,344 | $60K | Reduced | Mar 2026 |
| 14 | Quantinno Capital Management Lp | 20,000 | $44K | — | Mar 2026 |
| 15 | Susquehanna International Group, Llp | 12,771 | $28K | Reduced | Mar 2026 |
| 16 | Royal Bank Of Canada | 12,239 | $27K | Added | Mar 2026 |
| 17 | Northwestern Mutual Wealth Management Co | 10,005 | $21K | — | Dec 2025 |
| 18 | Morgan Stanley | 8,540 | $18K | Reduced | Dec 2025 |
| 19 | Wells Fargo & Company/mn | 7,005 | $15K | New | Mar 2026 |
| 20 | Innovative Asset Advisors Group, Llc | 4,900 | $11K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 78,090 | $201K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 23,036 | $59K | Feb 2026 |
| 3 | Fidelity Series Total Market Index Fund | 18,649 | $48K | Feb 2026 |
| 4 | Fidelity Nasdaq Composite Index Fund | 8,519 | $22K | Feb 2026 |
| 5 | Schwab Total Stock Market Index Fund | 6,500 | $16K | Jan 2026 |
Valuation
Market Cap
$43.5M
Enterprise Value
$27.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.04x
P/B
2.37x
P/S
—
P/FCF
-1.45x
EV/EBITDA
—
Shares Out
14.6M
Financials (TTM)
Revenue
$0
Net Income
-$14.1M
EBITDA
-$28.0M
Free Cash Flow
-$30.0M
Op Cash Flow
-$30.0M
EPS Basic
$-1.07
EPS Diluted
$-0.80
EPS Forward
$-1.19
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$29.8M
Total Liab.
$11.5M
Total Equity
$18.3M
Cash
$18.3M
LT Debt
$2.4M
Book Value/Sh
$1.25
Debt/Equity
0.17x
Current Ratio
2.43
Quick Ratio
2.43
Returns & Growth
ROE
-51.5%
ROA
-40.2%
ROIC
-108.5%
Rev Growth YoY
-100.0%
EPS Growth YoY
+61.8%
Price Returns
2W
+13.4%
1M
+5.3%
3M
-8.1%
6M
-4.4%
12M
-53.3%
Technicals
52W High
$6.95
52W Low
$2.09
50d MA
$2.53
200d MA
$2.73
RSI (14)
58.00
ATR (14)
$0.67
Beta
-1.34
Avg Volume
3.8M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
4
Ex-Div Date
Apr 28, 2014
Analyst Price Targets
Consensus
$4.00
High
$5.00
Low
$3.00
Median
$4.00
Data updated apr 27, 2026 7:33am
· Source: financialmodelingprep.com